The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Correspondence
PreviousPrevious
Volume 359:426-427 July 24, 2008 Number 4
NextNext

Telmisartan, Ramipril, or Both in Patients at High Risk of Vascular Events

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF
-PDA Full Text
-Purchase this article

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited
-E-mail When Letters Appear

More Information
-Related Article
by McMurray, J. J.V.
-Related Article
by The ONTARGET Investigators
-PubMed Citation
To the Editor: The investigators of the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial (ONTARGET) (April 10 issue)1 report that telmisartan is equivalent to ramipril in patients with vascular disease or high-risk diabetes. However, the primary composite end point of death from cardiovascular causes, myocardial infarction, stroke, or hospitalization for heart failure was not lower in the combination-therapy group than in the group receiving ramipril alone, even though blood-pressure levels in the combination-therapy group were 2.4/1.4 mm Hg lower than those in the ramipril group throughout the study period. Still more disturbing was a trend in . . . [Full Text of this Article]



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.